(state or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Exhibit No. | Description | |||||||
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |
KEROS THERAPEUTICS, INC. | ||||||||
By: | /s/ Jasbir Seehra | |||||||
Jasbir Seehra, Ph.D. Chief Executive Officer |
Cover |
Jul. 24, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jul. 24, 2023 |
Entity Registrant Name | Keros Therapeutics, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39264 |
Entity Tax Identification Number | 81-1173868 |
Entity Address, Address Line One | 1050 Waltham Street |
Entity Address, Address Line Two | Suite 302 |
Entity Address, City or Town | Lexington |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02421 |
City Area Code | 617 |
Local Phone Number | 314-6297 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | KROS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001664710 |
Amendment Flag | false |
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end